

Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
("Ascendis Health" or "the Company")



DISPENSATION ON 60 DAY RULE TO DISPATCH CIRCULAR

Shareholders are referred to the announcement released on 1 February 2022, wherein shareholders were, *inter alia*, advised that Ascendis Health SA Holdings Proprietary Limited ("**AHSA**"), a wholly-owned subsidiary of Ascendis Health, had concluded an agreement in terms of which it would dispose of its direct and indirect interest in the entities through which the business known as "Pharma" operates (the "**Pharma Business**") to Pharma-Q Holdings Proprietary Limited and Imperial Logistics Limited (the "**Pharma-Q/Imperial Pharma Disposal**").

Shareholders are further referred to the announcement released on 19 July 2022, wherein shareholders were advised that AHSA had concluded an agreement in terms of which it would dispose of the Pharma Business to Austell Pharmaceuticals Proprietary Limited in the event that shareholders do not approve the Pharma-Q/Imperial Pharma Disposal (the "**Austell Pharma Disposal**").

Ascendis Health has received informal approval from the JSE in respect of the category 1 transaction circular to Ascendis Health shareholders in respect of the Pharma-Q/Imperial Pharma Disposal and expects to issue the circular on or about 13 September 2022. To this end, the Company has received a further dispensation from compliance with paragraph 9.20(b) of the JSE Limited Listings Requirements in respect of the Pharma-Q/Imperial Pharma Disposal, such that a circular containing details of the Pharma-Q/Imperial Pharma Disposal and the Austell Pharma Disposal, as well as a notice of general meeting to obtain the approval of shareholders for the Pharma-Q/Imperial Pharma Disposal and the Austell Pharma Disposal must now be issued on or before 30 September 2022.

5 September 2022
Bryanston

Sponsor



Questco Corporate Advisory Proprietary Limited